HC Wainwright Issues Pessimistic Forecast for CRBP Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Free Report) – Analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now anticipates that the biopharmaceutical company will post earnings of ($6.61) per share for the year, down from their prior forecast of ($6.11). HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($6.35) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q4 2026 earnings at ($1.73) EPS, FY2027 earnings at ($6.13) EPS, FY2028 earnings at ($5.28) EPS, FY2029 earnings at ($2.19) EPS and FY2030 earnings at ($0.09) EPS.

CRBP has been the subject of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Thursday, October 15th. Oppenheimer restated an “outperform” rating on shares of Corbus Pharmaceuticals in a research report on Wednesday. Mizuho dropped their price objective on shares of Corbus Pharmaceuticals from $24.00 to $23.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Wall Street Zen downgraded shares of Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.67.

Check Out Our Latest Research Report on CRBP

Corbus Pharmaceuticals Stock Down 0.6%

Shares of NASDAQ CRBP opened at $3.39 on Thursday. Corbus Pharmaceuticals has a 1-year low of $2.81 and a 1-year high of $12.88. The business’s fifty day moving average price is $5.67 and its two-hundred day moving average price is $8.34.

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.54).

Insider Activity

In related news, major shareholder Cormorant Asset Management, Lp sold 425,000 shares of the stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of $4.10, for a total value of $1,742,500.00. Following the completion of the transaction, the insider directly owned 1,919,971 shares of the company’s stock, valued at $7,871,881.10. This represents a 18.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CRBP. Orbimed Advisors LLC grew its stake in shares of Corbus Pharmaceuticals by 8.8% in the first quarter. Orbimed Advisors LLC now owns 1,737,287 shares of the biopharmaceutical company’s stock worth $16,313,000 after purchasing an additional 140,000 shares in the last quarter. Exome Asset Management LLC raised its stake in shares of Corbus Pharmaceuticals by 67.8% during the first quarter. Exome Asset Management LLC now owns 234,136 shares of the biopharmaceutical company’s stock valued at $2,199,000 after purchasing an additional 94,593 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Corbus Pharmaceuticals by 288.4% during the third quarter. Marshall Wace LLP now owns 308,138 shares of the biopharmaceutical company’s stock valued at $2,102,000 after purchasing an additional 228,807 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Corbus Pharmaceuticals by 76.6% in the first quarter. Dimensional Fund Advisors LP now owns 136,602 shares of the biopharmaceutical company’s stock worth $1,281,000 after purchasing an additional 59,248 shares during the period. Finally, Seven Fleet Capital Management LP lifted its holdings in Corbus Pharmaceuticals by 51.0% in the first quarter. Seven Fleet Capital Management LP now owns 85,687 shares of the biopharmaceutical company’s stock worth $805,000 after purchasing an additional 28,937 shares during the period. Institutional investors and hedge funds own 64.64% of the company’s stock.

Corbus Pharmaceuticals News Roundup

These are some of the CRBP news items that stood out recently:

  • Positive Sentiment: Mizuho maintained an Outperform rating and lowered its target only modestly, from $24 to $23. HC Wainwright also reiterated its Buy rating and $35 target, signaling substantial potential upside in analysts’ view, though targets are not guarantees. Corbus Pharmaceuticals Stock Price Target Lowered at Mizuho
  • Negative Sentiment: The forecast changes were mixed but included notable reductions: HC Wainwright lowered its Q4 2026 and full-year 2026 EPS estimates, as well as estimates for 2029 and 2030. It raised its 2027 and 2028 estimates, but the continuing projected losses underline the company’s ongoing earnings risk. Analysts Offer Insights on Healthcare Companies
  • Negative Sentiment: Recent results add pressure: Corbus reported a quarterly loss of $1.81 per share, worse than the $1.27-per-share loss analysts expected. Taken together with lowered near-term forecasts, this may weigh on sentiment despite the bullish ratings and targets.

Corbus Pharmaceuticals Company Profile

(Get Free Report)

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company based in Norwood, Massachusetts. It develops investigational medicines, with current research focused on cancer and obesity. Its oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, and CRB-601, an antibody targeting the αvβ8 integrin. The company is also developing CRB-913, an investigational drug candidate designed to act on the cannabinoid CB1 receptor for obesity treatment. These candidates are in development and are not approved medicines.

Recommended Stories

Earnings History and Estimates for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.